GET DAILY SIGNALSAmphastar Pharmaceuticals (AMPH) Q3 2025 Earnings: Modest Revenue Growth and an Adjusted EPS Beat
Key Takeaways
- Amphastar Pharmaceuticals reported third-quarter 2025 net revenues of $191.8 million, a slight increase from $191.2 million in the prior-year period.
- Adjusted (non-GAAP) earnings per share came in at $0.93, topping the consensus estimate of roughly $0.77 to $0.79, while GAAP (generally accepted accounting principles) diluted EPS was $0.37, weighed down by a $23.1 million litigation provision.
- BAQSIMI delivered its highest quarterly sales ever at $53.6 million, up 14% year over year, while Primatene MIST grew 11% to $28.8 million.
- Gross margin narrowed to 51.4% from 53.3% a year earlier, reflecting pricing declines in glucagon and epinephrine products and the shift of BAQSIMI sales into cost of goods sold.
- Declines in glucagon (down 49%), epinephrine (down 12%), and lidocaine (down 19%) underscored competitive and pricing headwinds across the generic injectables portfolio.
- You can find more information about the ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- Explore Trending AI Robots to discover AI-driven trading strategies across the market.
Earnings Context and Why It Matters
Amphastar Pharmaceuticals is a specialty pharmaceutical company focused on technically difficult-to-manufacture injectable, inhalation, and intranasal products, along with insulin active pharmaceutical ingredients (APIs). Its third-quarter 2025 results, reported on November 6, 2025, arrive at a pivotal moment in the company's transition. Having assumed full global commercialization of BAQSIMI, its ready-to-use glucagon nasal powder, at the start of 2025, AMPH is reorienting its revenue mix toward proprietary and branded products even as several legacy generic injectables face intensifying competition. This quarter offers investors a clear view of whether the growth from BAQSIMI and Primatene MIST can offset margin pressure and declining volumes in older product lines. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter of 2025, Amphastar reported net revenues of $191.8 million, up modestly from $191.2 million a year earlier and above consensus estimates. On a non-GAAP basis, adjusted net income was $44.6 million, or $0.93 per diluted share, beating the consensus estimate of approximately $0.77 to $0.79 and marking a roughly 20% positive earnings surprise. On a GAAP basis, net income fell to $17.3 million, or $0.37 per diluted share, down from $0.78 a year earlier, primarily due to a $23.1 million litigation provision recorded in general and administrative expenses.
Product-level results were mixed. BAQSIMI posted record quarterly sales of $53.6 million, up 14% year over year including prior sales recorded by Eli Lilly under a transition service agreement. Primatene MIST grew 11% to $28.8 million. By contrast, glucagon injection sales fell 49% to $13.6 million, epinephrine declined 12% to $18.8 million, and lidocaine dropped 19% to $12.9 million. Other product sales rose 10% to $64.1 million, helped by the August 2025 launch of iron sucrose injection, which contributed $2.4 million. From what I see, the contrast between the branded products and the legacy portfolio highlights the ongoing shift.
Market Reaction and Investor Sentiment
Investor sentiment heading into the quarter had been cautious, with AMPH shares under pressure through much of 2025 amid concerns about generic pricing competition and margin erosion. The earnings beat on adjusted EPS and revenue, driven by record BAQSIMI sales, provided a positive counterpoint, though the sharp decline in GAAP profitability from the litigation charge and the continued slide in higher-margin legacy products tempered enthusiasm. The mixed picture likely kept the focus on whether the company's branded-product momentum can sustainably outweigh the structural pressures in its generic injectables business. I’m watching this closely as the company navigates these dynamics.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should watch how Amphastar manages the margin dynamics created by its evolving product mix. BAQSIMI remains the central growth driver, and management has indicated it holds roughly 55% to 60% of the ready-to-use glucagon market. Sustaining that position will depend on continued commercial execution, including the co-promotion arrangement with MannKind's sales force.
On the pipeline front, the company's exclusive licensing agreement with Nanjing Anji Biotechnology adds three early-stage peptide candidates targeting oncology and ophthalmology, broadening the portfolio beyond diabetes and complex generics. Management has also signaled progress on several regulatory programs, including a potential generic inhalation product (AMP-007) targeted for a mid-2026 launch and generic teriparatide (AMP-015) for the first half of 2026.
Key factors to monitor include gross margin trends as higher-margin legacy products such as glucagon and epinephrine multi-dose vials face continued pricing and competitive pressure, the pace of BAQSIMI and Primatene MIST growth, and any updates on the litigation for which the company recorded a $23.1 million provision and plans to appeal. Cost-control efforts and the rollout of newly approved products will also be important signals of the company's ability to protect profitability while funding its expanded pipeline.
Using Tickeron AI Tools for Deeper Analysis
In my view, tools like Tickeron’s AI Trend Prediction Engine can help investors track momentum in names like AMPH by highlighting pattern shifts and forecast signals that complement traditional earnings analysis. I ran a quick check on the stock’s recent performance metrics through the platform to see how the branded growth stacks up against broader sector trends. This approach keeps the focus on data-driven insights rather than speculation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AMPH's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for AMPH turned positive on October 30, 2026. Looking at past instances where AMPH's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on AMPH as a result. In 59 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The 50-day moving average for AMPH moved above the 200-day moving average on October 02, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +3.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMPH advanced for three days, in 254 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for AMPH moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 30 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
AMPH broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AMPH entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. AMPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.552) is normal, around the industry mean (7.659). P/E Ratio (16.103) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.640) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.522) is also within normal values, averaging (181.047).
The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is IRS Publication 544 on Sales and Other Dispositions of Assets?
Mode: How is the mode calculated in statistics?
AI Trading Bots: Top 10 Swing Traders, Virtual Accounts, on October 31, 2024
Understanding the Broadening Wedge Ascending (Bearish) Pattern in the Context of Psychological Dynamics in Pattern Trading
AI Aerospace & Defense Agent Hits 77.36% Win Rate and +strong performance as Pentagon Budget Surges to $1.5 Trillion
General Information
a manufacturer of proprietary injectable and inhalation products
Industry PharmaceuticalsGeneric
Advertisement